FHTX Earnings Date: Nov 4, 2026 (Estimated) — Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is FHTX's next earnings date?
Foghorn Therapeutics Inc. (FHTX) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.23 on revenue of $6.4M.
How did FHTX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Foghorn Therapeutics Inc. posted EPS of -$0.10 versus the -$0.24 estimate, a beat of 56.5%. Revenue was $16.1M against a $6.8M estimate. The stock's 1-day post-earnings move was +14.1%.
How much does FHTX stock move after earnings?
FHTX beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.9% (up or down) in the day after earnings.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.24 | -0.10 | +56.52% | $16.1M | ✅ Beat | +14.14% | +36.07% | -0.20% |
| 2026-05-07 | Q1 2026 | -0.31 | -0.29 | +6.45% | $3.3M | ✅ Beat | -10.26% | -10.90% | -20.30% |
| 2026-03-11 | Q4 2025 | -0.27 | -0.34 | -25.93% | $9.2M | ❌ Miss | -12.92% | -13.63% | -18.76% |
| 2025-11-05 | Q3 2025 | -0.30 | -0.25 | +16.67% | $8.2M | ✅ Beat | +13.31% | +25.78% | +29.75% |
| 2025-08-05 | Q2 2025 | -0.31 | -0.28 | +9.68% | $7.6M | ✅ Beat | -2.72% | -8.37% | +2.53% |
| 2025-03-06 | Q4 2024 | -0.27 | -0.23 | +14.81% | $2.9M | ✅ Beat | +0.44% | -0.44% | -23.56% |
| 2024-11-04 | Q3 2024 | -0.44 | -0.31 | +29.55% | $7.8M | ✅ Beat | -0.72% | +12.65% | -8.19% |
| 2024-03-07 | Q4 2023 | -0.76 | -0.57 | +25.00% | $5.8M | ✅ Beat | +0.59% | -0.44% | +4.57% |
Showing last 8 quarters.